fashion -WSS

fashion

author：fashion 2025-09-30 16:23:22 - browse：456

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Scientific mystery highlights the blind spots in genomics databases

WSS

Chinese researcher claims birth of first gene

Diabetes management: Digital health tools fall short, study says

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Medical devices makers are asking for forgiveness, not permission

Medicare Advantage 2025 payments will dip, Biden administration says

Republican states more likely to report Covid vaccine side effects

hotspot

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

'Patient friction coefficient' can gauge a clinical trial's patient burden

Apple is now the first public company to be valued at $3 trillion

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

The high cost of giving birth even with insurance

Steward Health Care expansion into Malta flopped

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Republican states more likely to report Covid vaccine side effects

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Illumina, CRISPR, Regeneron

focus

Yancopoulos of Regeneron works to expand Dupixent success

'Patient friction coefficient' can gauge a clinical trial's patient burden

6 surprising facts about sugar

First Opinion on colorectal cancer screening: letter and response

Scientific mystery highlights the blind spots in genomics databases

Oral obesity drug from Viking Therapeutics hits key early target

Wikipedia

entertainment

explore

focus